宏源药业：2025年净利润同比预增119.57%—166.2%

Core Viewpoint - Hongyuan Pharmaceutical (301246) expects a significant increase in net profit for 2025, projecting a range of 113 million to 137 million yuan, representing a year-on-year growth of 119.57% to 166.2% [1] Group 1 - The demand for new energy vehicles continues to grow, contributing positively to the company's performance [1] - The energy storage market is experiencing rapid growth, further enhancing the profitability of the company's lithium hexafluorophosphate business [1]